Investors

Sarcomatrix fully supports the development of gene and cell therapies and looks forward to the day they cure afflicted individuals. Until that day comes, we’re committed to polytherapy, which involves using multiple treatments in combination to achieve the best possible outcome. This approach may be particularly useful in the treatment of complex diseases like muscular dystrophy, where a single treatment may not be enough to address all the symptoms and underlying causes of the disease. We fully engage individuals and families at each step of the drug development process and look forward to partnering with patient advocacy groups like Cure CMD and PPMD to keep the community informed.